Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klaus Rose

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Expert Opinion on Pharmacotherapy|April 21, 2025
Drug development in dermatology: challenges in treating young patientsKlaus Rose, Tomoko Maeda-Chubachi, Jane M Grant-Kels
Swiss Medical Weekly|May 27, 2020
Comment on: Mumme M, et al. Tissue engineering for paediatric patients. Swiss Med Wkly. 2019.149.w20032Klaus Rose, Jane M Grant-Kels, David Neubauer, et al.
Rambam Maimonides Medical Journal|July 16, 2021
Letter to the Editor: Delayed Presentation of Non-COVID-19 Patients During the COVID-19 Pandemic Is Not Limited to ChildrenKlaus Rose, Oishi Tanjinatus, Jane Grant-Kels, et al.
Expert Opinion on Pharmacotherapy|September 17, 2025
Navigating regulatory challenges in pediatric epilepsy pharmacotherapy: pathways to safe and effective treatmentsGianmichele Villano, Gianluca D'Onofrio, Antonella Riva, et al.
World Journal of Methodology|July 10, 2024
Did pediatric drug development advance epilepsy treatment in young patients? It is time for new research goalsEarl B Ettienne, Emilio Russo, Pasquale Striano, et al.
Journal of Law and Medicine|January 9, 2025
Deception and Fraud in the Justification of "Pediatric Drug Development": A Challenge at the Interface of Medicine and LawKlaus Rose, Jane M Grant-Kels, Pasquale Striano, et al.
Expert Opinion on Drug Metabolism & Toxicology|August 25, 2022
Pharmacokinetic considerations surrounding the use of levetiracetam for seizure prophylaxis in neurocritical care - an overviewGianluca D'Onofrio, Antonella Riva, Elisabetta Amadori, et al.
Rambam Maimonides Medical Journal|March 29, 2021
COVID-19 and Treatment and Immunization of Children-The Time to Redefine Pediatric Age Groups is HereKlaus Rose, Jane M Grant-Kels, Earl B Ettienne, et al.
Pediatric Blood & Cancer|February 23, 2021
Comment on: A review of the experience with pediatric written requests issued for oncology drug productsKlaus Rose, Jane M Grant-Kels, Earl B Ettienne, et al.
Journal of Law and Medicine|June 5, 2023
"Pediatric" Drug Studies Might Be the Largest Abuse in Medical Research in History. It Is Time for Lawyers to Step InKlaus Rose, Jane M Grant-Kels, Pasquale Striano, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Expert Opinion on Pharmacotherapy|April 21, 2025
Drug development in dermatology: challenges in treating young patientsKlaus Rose, Tomoko Maeda-Chubachi, Jane M Grant-Kels
Swiss Medical Weekly|May 27, 2020
Comment on: Mumme M, et al. Tissue engineering for paediatric patients. Swiss Med Wkly. 2019.149.w20032Klaus Rose, Jane M Grant-Kels, David Neubauer, et al.
Rambam Maimonides Medical Journal|July 16, 2021
Letter to the Editor: Delayed Presentation of Non-COVID-19 Patients During the COVID-19 Pandemic Is Not Limited to ChildrenKlaus Rose, Oishi Tanjinatus, Jane Grant-Kels, et al.
Expert Opinion on Pharmacotherapy|September 17, 2025
Navigating regulatory challenges in pediatric epilepsy pharmacotherapy: pathways to safe and effective treatmentsGianmichele Villano, Gianluca D'Onofrio, Antonella Riva, et al.
World Journal of Methodology|July 10, 2024
Did pediatric drug development advance epilepsy treatment in young patients? It is time for new research goalsEarl B Ettienne, Emilio Russo, Pasquale Striano, et al.
Journal of Law and Medicine|January 9, 2025
Deception and Fraud in the Justification of "Pediatric Drug Development": A Challenge at the Interface of Medicine and LawKlaus Rose, Jane M Grant-Kels, Pasquale Striano, et al.
Expert Opinion on Drug Metabolism & Toxicology|August 25, 2022
Pharmacokinetic considerations surrounding the use of levetiracetam for seizure prophylaxis in neurocritical care - an overviewGianluca D'Onofrio, Antonella Riva, Elisabetta Amadori, et al.
Rambam Maimonides Medical Journal|March 29, 2021
COVID-19 and Treatment and Immunization of Children-The Time to Redefine Pediatric Age Groups is HereKlaus Rose, Jane M Grant-Kels, Earl B Ettienne, et al.
Pediatric Blood & Cancer|February 23, 2021
Comment on: A review of the experience with pediatric written requests issued for oncology drug productsKlaus Rose, Jane M Grant-Kels, Earl B Ettienne, et al.
Journal of Law and Medicine|June 5, 2023
"Pediatric" Drug Studies Might Be the Largest Abuse in Medical Research in History. It Is Time for Lawyers to Step InKlaus Rose, Jane M Grant-Kels, Pasquale Striano, et al.
Pageof 5